By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Would you give one breath to save your life?

OneBreath™ is a patented technology with the potential to accurately detect lung cancer earlier and more cost effectively than currently available screening methods.1

Human Breath is a powerful reservoir of untapped biological data

We have created a technology to quantify specific molecular markers in the Breath to diagnose disease -- starting with lung cancer.
Breath Technology
01 problem- Lung Cancer

Lung cancer is the most deadly cancer in the United States

Lung cancer kills over 130,000 people annually, causing more deaths than colon, breast, and prostate cancer combined. Low screening compliance rates and limited accessibility of current screening methods highlights a glaring need for an alternative screening method to better serve the 14.5 million people at risk of developing lung cancer.
02 problem- Lung Cancer

Early diagnosis is the key to successful treatment of lung cancer.

OneBreath™ is designed to provide a safe, convenient, and affordable way to accurately identify lung cancer in at risk patients, before they know they have a problem.1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
info icon
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
03 problem- Lung Cancer

OneBreath™: A Reliable, Accessible, and Cost-Effective Solution

OneBreath™ has the potential to transform the lung cancer screening landscape with the ability to detect early-stage lung cancer.1
info icon
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

Our groundbreaking OneBreath™ technology is a cutting-edge breath analysis system designed to deliver an accurate, safe, and accessible lung cancer screening tool to patients and providers.1


OneBreath™ utilizes a patented chemical formulation and micro-reactor to capture and quantitatively count organic compounds contained in a single breath, with the ability to detect even early stage lung cancers.1
Breath Collection
Patients provide one complete breath via a unique collection system in less than 30 seconds.
Breath Analysis & Processing
In a simple automated process, the OneBreath™ micro-reactor captures a spectrum of organic compounds contained in the breath. Once captured, the sample is analyzed in our laboratory.
Get Results
Results will be available to physicians and patients within 3-4 business days.


To the promise of breath based lung cancer diagnostics and what Breath diagnostics could offer patients -- if we can obtain these.
"Technology like OneBreath has so much potential for improving and saving lives."
Dr. Kevin Gardner
Executive VP Research and Innovation, University of Louisville
Michael Nantz
Founder, Organic Chemist
Dr. Michael H. Nantz currently serves as the Professor and Chair of the Department of Chemistry at the University of Louisville. Dr. Nantz has made significant contributions to the world of science and academia. Dr. Nantz's research expertise spans various areas, including cationic lipids and polymers for gene delivery, peptide-based prodrugs for cancer chemotherapeutics, applications of nanoparticle-peptide conjugates, and, of course, breath analysis research such quantitative analysis of exhaled carbonyl compounds. He has a prolific publication record, with many notable publications and is a contributor to several patents and licenses related to his research, including those in the field of cationic transport reagents, polyfunctional cationic cytofectins, breath analysis, and more. His innovations have had a significant impact on various areas of science and technology.
mail icon
Xiao-An (Sean) Fu
Founder, Chemical Engineer
Xiao-An (Sean) Fu is a Professor of Chemical Engineering at the University of Louisville. His current research interests include chemical microsensors, microreactors, breath analysis for development of a noninvasive diagnostic tool for detection of early lung cancer, trace gas detection, active tuberculosis and other pulmonary diseases, analysis of neurotransmitter, and advanced semiconductor thin films for integrated circuit and solar cell applications. He has published more than 60 papers in refereed journals and conference proceedings, and has received three U.S. patents. He was a key contributor to a number of research projects funded by DARPA and NASA including SiC MEMS and SiC JFET-based integrated circuits for high temperature applications. He invented a process for deposition of low stress polycrystalline SiC suitable as MEMS structure materials.
mail icon
Victor van Berkel
CMO, Founder, and Director
Dr. Victor van Berkel, MD, PhD is a Professor of Surgery in the Department of Cardiovascular and Thoracic Surgery at the University of Louisville, as well as Chief of the Division of Thoracic Surgery and is currently the vice-chair of the Department. He is a co-investigator for several oncologic clinical trials through the Brown Cancer Center, and sits on two FDA panels that deal with the approval of medical devices. In addition to his clinical practice, he has an active research lab - his research on the use of breath analysis to identify lung cancer led to him being a cofounder of Breath Diagnostics, Inc.
mail icon
Michael Bousamra
Founder and Director
Dr. Bousamra is a thoracic (chest) surgeon with Ascension Michigan in Detroit, Warren, and Southfield, specializing in the care of patients with lung cancer, esophageal cancer, and in the full spectrum of malignant and benign non-cardiac diseases of the chest. He is also chief of thoracic surgery in SE Michigan and is responsible for the development and implementation of a comprehensive lung cancer program focusing on early detection. A graduate of University of Michigan Medical School and a member of the American Association for Thoracic Surgery, he has authored over 50 peer-reviewed publications and holds several patents on methods to detect cancer.
mail icon
Phil Douglas
Chairman and Director
Phillip B. Douglas has 40 years of experience as a seasoned and innovative leader who has management and board experience which spans diverse organizational settings and industries. In addition to serving as a Director of Breath Diagnostics, Mr. Douglas currently serves on the Board of Directors of Oceans Healthcare, PartnerCare, Ernest Healthcare, The Ear Nose Throat & Plastic Surgery Associates (“ENTPSA”), Palmetto Technology Group (“PTG”) and Volta Inc. Previously Phil was the Executive Chairman of KureSmart Pain Management and Chairman and CEO of LifeCare Health Partners, which operated 25 locations in 9 states and experienced significant revenue and earnings growth under Mr. Douglas’ leadership. Mr. Douglas previously held senior executive positions with Humana and United Healthcare. Mr. Douglas is a graduate of the University of Kentucky and was a CPA with Price Waterhouse Coopers.
mail icon
Jeff Rich
Dr. Rich is currently the Cleveland Clinic’s Chairman of Operations and Strategy for the Sydell and Arnold Miller Family Heart & Vascular Institute. He previously served as the Surgical Director of the Sentara Cardiac Research Institute, as past President of the Society of Thoracic Surgeons and held leadership positions within the National Quality Forum (NQF). In addition, Dr. Rich served as the Director of the Center for Medicare at the Centers for Medicare and Medicaid Services (CMS). He testified four times before Congress and has served on Federal Advisory Committees for CMS as well as the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee.
mail icon
Ivan Lo
CEO and Director
Ivan Lo is the founder of Wealth Stream Capital Corp, a family office that invests in private and public companies across various sectors. WSCC was formed as a result of the seed and early-stage investments Ivan Lo has made, which have led to multiple exits and companies that have surpassed unicorn valuations. Ivan has led multiple strategic financing initiatives, and has been instrumental in the success of numerous private and public companies, playing a key role in the structure and financing of companies across various sectors. He has funded over 100 private and public companies who collectively have raised over $1 billion.
mail icon
OneBreath™ by Breath Diagnostics

OneBreath™ may save your life.

Contact us to discover the future of lung cancer screening or click below to learn more.1